Published in Women's Health Weekly, October 10th, 2002
Under the terms of this agreement, Quintiles' commercialization unit, Innovex, will provide a dedicated team of 55 sales representatives on a 3-year, fee-for-service basis, to commercialize the following products:
{bullet} Prochieve 8%, approved for progesterone supplementation or replacement as part of an assisted reproductive technology (ART) treatment for infertile women with progesterone deficiency and secondary amenorrhea;
{bullet} Prochieve 4%, approved for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.